Stefano Sorrentino

Dr. Stefano Sorrentino

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Giuseppe Di FedeGiuseppe Di Fede
Giuseppe Di Fede
MCMarcella Catania
Marcella Catania
EMEmanuela Maderna
Emanuela Maderna
RGRoberta Ghidoni
Roberta Ghidoni
LBLUISA BENUSSI
LUISA BENUSSI
FTFabrizio Tagliavini
Fabrizio Tagliavini
Protein misfolding and aggregation is a central feature of several neurodegenerative disorders including Alzheimer’s disease (AD), in which assemblies of amyloid β (Aβ) peptides accumulate in the brain in the form of parenchymal and/or vascular amyloid. A widely accepted concept is that AD is characterized by distinct clinical and neuropathological phenotypes. Recent studies revealed that Aβ assemblies might have structural differences among AD brains and that such pleomorphic assemblies can correlate with distinct disease phenotypes. We found that in both sporadic and inherited forms of AD, amyloid aggregates differ in the biochemical composition of Aβ species. These differences affect the physicochemical properties of Aβ assemblies including aggregation kinetics, resistance to degradation by proteases and seeding ability. Aβ-amyloidosis can be induced and propagated in animal models by inoculation of brain extracts containing aggregated Aβ. We found that brain homogenates from AD patients with different molecular profiles of Aβ are able to induce distinct patterns of Aβ-amyloidosis when injected into mice. Overall these data suggest that the assembly of mixtures of Aβ peptides into different Aβ seeds leads to the formation of distinct subtypes of amyloid having distinctive physicochemical and biological properties which result in the generation of distinct AD molecular subgroups.

Verified
Journal Article
Open access
PDF file
SSStefano Sorrentino
Stefano Sorrentino
RARoberto Ascari
Roberto Ascari
EMEmanuela Maderna
Emanuela Maderna
MCMarcella Catania
Marcella Catania
BGBernardino Ghetti
Bernardino Ghetti
Giuseppe Di FedeGiuseppe Di Fede
Giuseppe Di Fede
Alzheimer’s disease (AD) is increasingly recognized as a highly heterogeneous disorder occurring under distinct clinical and neuropathological phenotypes. Despite the molecular determinants of such variability not being well defined yet, microglial cells may play a key role in this process by releasing distinct pro- and/or anti-inflammatory cytokines, potentially affecting the expression of the disease. We carried out a neuropathological and biochemical analysis on a series of AD brain samples, gathering evidence about the heterogeneous involvement of microglia in AD. The neuropathological studies showed differences concerning morphology, density and distribution of microglial cells among AD brains. Biochemical investigations showed increased brain levels of IL-4, IL-6, IL-13, CCL17, MMP-7 and CXCL13 in AD in comparison with control subjects. The molecular profiling achieved by measuring the brain levels of 25 inflammatory factors known to be involved in neuroinflammation allowed a stratification of the AD patients in three distinct “neuroinflammatory clusters”. These findings strengthen the relevance of neuroinflammation in AD pathogenesis suggesting, in particular, that the differential involvement of neuroinflammatory molecules released by microglial cells during the development of the disease may contribute to modulate the characteristics and the severity of the neuropathological changes, driving—at least in part—the AD phenotypic diversity.

1 April 2022 in Current Opinion in Biotechnology
Verified
Journal Article
Open access
SSStefano Sorrentino
Stefano Sorrentino
Alessandro PoliniAlessandro Polini
Alessandro Polini
VAValentina Arima
Valentina Arima
ARAlessandro Romano
Alessandro Romano
AQAngelo Quattrini
Angelo Quattrini
Lorenzo MoroniLorenzo Moroni
Lorenzo Moroni